Physostigmine Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the use of physostigmine during breastfeeding. It should be used during breastfeeding if it is essential to the mother’s health.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information in nursing mothers was not found as of the revision date. In animals, cholinergic drugs increase oxytocin release,[1] and physostigmine increases serum prolactin in humans.[2,3] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
References
1.
Clarke G, Fall C, Lincoln D, et al. Effects of cholinoceptor antagonists on the suckling-induced and experimentally evoked release of oxytocin. Br J Pharmacol 1978;63:519-27. [PMC free article: PMC1668097] [PubMed: 566601]
2.
Risch S, Janowsky D, Siever L, et al. Cholinomimetic-induced co-release of prolactin and beta-endorphin in man. Psychopharmacol Bull 1982;18:21-5. [PubMed: 6296908]
3.
Risch S, Janowsky D, Siever L, et al. Correlated cholinomimetic-stimulated beta-endorphin and prolactin release in humans. Peptides 1982;3:319-22. [PubMed: 6289276]
Substance Identification
Substance Name
Physostigmine
CAS Registry Number
57-47-6
Drug Class
Breast Feeding
Lactation
Milk, Human
Cholinesterase Inhibitors
Parasympathomimetics
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
